

# Effects of HIV infection and gender on metabolite level changes in the basal ganglia in children from 5 to 7 years

## Introduction


- **What is magnetic resonance spectroscopy (MRS)?** MRS is a non-invasive technique measuring metabolite levels in localized brain tissue.
- **What metabolites are measured?** Metabolites measure different aspects of brain health. Choline (GPCr) is associated with cellular density. Creatine (CrPCr) is related to energy metabolism. NAA (N-acetyl-aspartate) represents neuronal density and integrity. Glutamate is a neurotransmitter. Myo-inositol is considered a glial marker [1].
- **Why look at HIV-infected children stable on ART?** Early initiation of antiretroviral therapy (ART) has been shown to be particularly beneficial to children born HIV-infected [2,3], however the long-term impact of ART usage and HIV infection on child brain development is unknown. A deeper understanding of neurodevelopment of children stable on ART will allow for better overall health care and management of ART to ensure ideal development.
- **Why look at gender?** Gender-specific maturational changes occur in the developing brain [4]. MRS studies focused on age dependent changes in healthy children have not observed any gender differences [5,6]. Metabolites may shed light on the underlying mechanisms of gender related brain maturation.
- **Why look at the basal ganglia?** The basal ganglia (BG) play an important role in motor control as well as executive and limbic functions [7]. The basal ganglia is vulnerable to damage from HIV infection in children [8,9], and previous MRS studies in HIV-infected children have found altered neurometabolism in the BG [8,10].
- **Why look at metabolite level trajectories?** Metabolite levels are expected to remain relatively constant in childhood [5,6]. Metabolite level increases or decreases in childhood represent neurodevelopmental delay, possible damage/recovery or gender-specific maturation differences.

## Study

Single voxel <sup>1</sup>H-MRS (SVS) data were acquired in the right BG on a Siemens 3T Allegra Head Scanner (Siemens, Erlangen, Germany) in Cape Town, South Africa on a cohort of HIV-infected and HIV-uninfected children at ages 5 and 7. MRS data were acquired with a real-time motion and B<sub>0</sub> corrected [11] point resolved spectroscopy (PRESS) sequence (TR 2000 ms, TE 30 ms, 64 averages, Scan time: 2:16 min). Absolute metabolite levels were determined with LCMoDel [12]. R was used for statistical analysis [13].

**Subjects:** We obtained MRS data in the BG on fifty-six 5-year old (30 female; mean age ± standard deviation = 5.5 ± 0.4 years; 36 HIV-infected/20 HIV-uninfected) and eighty-one 7-year old children (44 female; 7.2 ± 0.3 years; 46 HIV-infected/35 HIV-uninfected), with thirty-two children imaged at both ages. HIV-infected children were a subset of the children with HIV early ART (CHER) trial [2,3], and all initiated ART between 6 weeks and 1 year of age (except two children who started by 18 months).


## Results: HIV-infected and HIV-uninfected



**Results:** Mean NAA, creatine and glutamate metabolite levels remained constant from age 5 to 7 years among all children. Choline levels remained constant among control children, however we observed a significant decrease (unpaired t-test:  $p = 0.01$ ) among HIV-infected children. We observed a significant decrease in myo-inositol across all children (unpaired t-test:  $p = 0.0003$ ), that is more significant among the HIV-infected children (unpaired t-test:  $p = 0.001$ ) compared to the HIV-uninfected children (unpaired t-test:  $p = 0.08$ ).

**Interpretation:** Constant NAA, creatine and glutamate levels indicate healthy development among HIV-infected children. Decreased myo-inositol levels are unexpected, and may indicate normal development between 5 and 7 years. The fact that the difference is more significant among the HIV-infected children may be due to the larger sample size (82 HIV-infected children/55 HIV-uninfected children). Previous studies may not have observed decreases in myo-inositol because of the wide age ranges used [5,6]. The high mean choline levels at age 5 in infected children suggest possible regional inflammation, followed by recovery at age 7.

## Results: Girls and Boys



**Results:** NAA and creatine levels remain constant. Myo-inositol significantly decreases across both boys (unpaired t-test:  $p = 0.006$ ) and girls (unpaired t-test:  $p = 0.02$ ). Glutamate levels are constant among boys; however we found a significant decrease from age 5 to 7 in girls (unpaired t-test:  $p = 0.03$ ) and lower mean glutamate levels in girls compared to boys at age 7 (unpaired t-test:  $p = 0.03$ ). Choline levels decrease in boys only (unpaired t-test:  $p = 0.04$ ) from 5 to 7 years, and boys have significantly higher choline levels at age 5 than girls (unpaired t-test:  $p = 0.01$ ). Further investigation finds the decreased choline levels are driven by HIV-infected boys (unpaired t-test:  $p = 0.007$ ).

**Interpretation:** Constant NAA and creatine levels represent healthy brain maturation across gender. The decrease in myo-inositol is observed across boys and girls, and is therefore gender independent. The significant reduction in glutamate levels in girls is unexpected, and suggests a gender difference in neurological maturation in the basal ganglia between ages 5 and 7. The significant decrease in choline levels in HIV-infected boys only provides insight into the above observed high mean choline in HIV-infected children at age 5. Further investigation into why 5 year old boys had higher choline levels are necessary.

## Summary

1. NAA and creatine levels remain constant across ages 5 and 7, independent of HIV status and gender;
2. HIV-infected children show a significant decrease in mean choline levels at age 7, driven by boys;
3. All children exhibit a significant decrease in myo-inositol levels from age 5 to 7 years;
4. Glutamate levels decreased significantly from age 5 to 7 among girls only.

## References

- [1] Soares, D. and Law, M. 2009. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. *Clinical Radiology* 64:12-21. [2] Cotton MF, Violaro A, Obwomeke K, et al. 2013. Early time limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: Results from the children with HIV early antiretroviral (CHER) randomised trial. *Lancet*. 382: 1555-63. [3] Violaro A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV infected infants. *N Engl J Med* 2008; 359: 2233-44. [4] Giedd, J.N. et al. 1996. Quantitative magnetic resonance imaging of human brain development: Ages 4 - 18. *Cereb. Cortex*. 6(4): 551-559. [5] Pouwels, P.J.W. et al. 1999. Regional Age Dependence of Human Brain Metabolites from Infancy to Adulthood as Detected by Quantitative Localized Proton MRS. *Pediatric Research* 44:474-485. [6] Kreis, R., Ernst, T. and Ross, B.D. 1993. Magnetic Resonance in Medicine. 30(4):424-437. [7] Middleton FA, Strick PL. 2000. Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies. *Brain Cogn* 42: 183-200. [8] Pavlakis SG, Lu D, Frank Y, et al. 1995. Magnetic resonance spectroscopy in childhood AIDS encephalopathy. *Pediatr Neurol*. 12: 277-82. [9] Hoare, J. et al. 2013. Systematic review of neuroimaging studies in vertically transmitted HIV positive children and adolescents. *Metabolic brain disease*. 29(2):221-9. [10] Keller, M. et al. 2004 Altered neurometabolite development in HIV-infected children: Correlation with neuropsychological scores. *Neurology* 62:1810-1817. [11] Hess et al. 2011. Real-time motion and B<sub>0</sub> corrected single voxel spectroscopy using volumetric navigators. *Mag Res in Med* 66:314-323. [12] Provencher, SW. 2001. Automatic quantitation of localized in vivo <sup>1</sup>H spectra with LCMoDel. *NMR Biomed*. 14(4):260-4. [13] R Core Team. 2015. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.

## Acknowledgements

Support for this study was provided by NRF/DST South African Research Chairs Initiative; US National Institute of Allergy and Infectious Diseases (NIAID) through the CIPRA network, Grant U19 AI53217; NIH grants R01HD071664 and R21MH096559; NRF grant CPR20110614000019421, and the Medical Research Council (MRC). We thank the CUBIC radiographers Marie-Louise de Villiers and Nailah Maroof, our research staff Thandwi Hamana and Rosy Khethelo, and Shabir A Madhi for access to control participants on the CIPRA-SA04 trial.